• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roivant Sciences Ltd (NQ: ROIV )

    11.31 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 72
    Open 11.31
    Bid (Size) 11.03 (10)
    Ask (Size) 11.63 (10)
    Prev. Close 11.31
    Today's Range 11.31 - 11.31
    52wk Range 8.245 - 13.24
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
    From Roivant Sciences
    Via GlobeNewswire

    Performance

    YTD
    -0.35%
    -0.35%
    1 Month
    -2.58%
    -2.58%
    3 Month
    -0.88%
    -0.88%
    6 Month
    -1.22%
    -1.22%
    1 Year
    +4.63%
    +4.63%

    More News

    Read More
    Evaluating Roivant Sciences: Insights From 6 Financial Analysts
    Via Benzinga
    The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
    Via Benzinga
    ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
    Via InvestorPlace
    Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
    Via Benzinga
    Where Roivant Sciences Stands With Analysts
    Via Benzinga
    The Analyst Landscape: 4 Takes On Roivant Sciences
    Via Benzinga
    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
    Via Benzinga
    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
    Via InvestorPlace
    Roivant Sciences Earnings Preview
    Via Benzinga
    3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
    Via InvestorPlace
    Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
    Via Benzinga
    Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
    Via Investor's Business Daily
    Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
    From Roivant Sciences
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
    Via Investor's Business Daily
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Earnings Scheduled For February 13, 2024
    Via Benzinga
    Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
    Via Investor's Business Daily
    Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.